The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

Abstract:

BACKGROUND:Despite recent advances in treating non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK-positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK-positive NSCLC. METHODS:Between 2011 and 2018, a total of 14 ALK-positive NSCLC patients treated with ICIs were evaluated retrospectively. Clinicopathologic features including age, PD-L1 expression, and treatment outcomes were analyzed. RNA expression level and cytolytic activity by ALK positivity were analyzed using The Cancer Genome Atlas (TCGA) and National Cancer Center Research Institute (NCCRI) data sets. RESULTS:A total of 13 patients (92.9%) received ALK inhibitors. Patients received a median of three (range 2-8) courses of therapy. The study included nine patients (64.3%) who were PD-L1-high (>50%) and four (28.6%) who were PD-L1-low (<50%). The objective response rate was 14.3% (2/14). The median progression-free survival time was 2.18 months (95% confidence interval [CI] 1.13 months-not reached [NR]). The median overall survival time was 5.67 months (95% CI 3.00 months-NR). RNA expression levels of CD274 were similar between the ALK-positive and negative groups in both TCGA and NCCRI datasets. RNA levels of CD8A in both TCGA and NCCRI data sets were nonsignificantly lower in the ALK-positive group. Cytolytic activity scores including interferon-γ-related response were lower in the ALK-positive group in the NCCRI but not TCGA dataset. CONCLUSIONS:Despite high PD-L1-positive rates, ICIs show limited efficacy in ALK-positive NSCLC. Decreased interferon-γ-related response may underlie these findings.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Heo JY,Park C,Keam B,Ock CY,Kim M,Kim TM,Kim DW,Kim SH,Kim YJ,Lee JS,Heo DS

doi

10.1111/1759-7714.13195

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

2117-2123

issue

11

eissn

1759-7706

issn

1759-7714

journal_volume

10

pub_type

杂志文章
  • Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports.

    abstract:BACKGROUND:Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the effective medicines in advanced lung adenocarcinoma leptomeningeal metastasis (LM) treatment in recent years. METHODS:This paper reports two cases of advanced lung adenocarcinoma with exon-EGFR19 mutation. LM occurred during gefit...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12049

    authors: Xing P,Li J,Shi Y,Zhang X

    更新日期:2014-01-01 00:00:00

  • Lung cancer surgery in HIV-infected patients: An analysis of postoperative complications and long-term survival.

    abstract:BACKGROUND:The purpose of this study was to investigate the risk factors of postoperative complications and reliable prognostic factors of long-term survival in HIV-infected patients with non-small cell lung cancer (NSCLC). METHODS:HIV-infected patients with NSCLC who underwent surgical treatment were retrospectively ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13519

    authors: Wang L,Chen Y,Wang Y,Liu J,Wen Z,Chen H,Zhu Y,Wang J,Wan L,Li F,Song Y

    更新日期:2020-08-01 00:00:00

  • Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

    abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12557

    authors: Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

    更新日期:2018-01-01 00:00:00

  • Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.

    abstract:BACKGROUND:CD73 induces the dephosphorylation of adenosine monophosphate converting it to adenosine, enabling malignancies to escape from immune surveillance. Although CD73 overexpression has been reported to be a poor prognostic factor in several malignancies including non-small cell lung cancer (NSCLC), its predictiv...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13346

    authors: Ishii H,Azuma K,Kawahara A,Kinoshita T,Matsuo N,Naito Y,Tokito T,Yamada K,Akiba J,Hoshino T

    更新日期:2020-04-01 00:00:00

  • Comparative study of esophagectomy, endoscopic therapy, and radiotherapy for cT1N0M0 esophageal cancer in elderly patients: A SEER database analysis.

    abstract:BACKGROUND:The number of patients diagnosed with early stage disease (T1a or T1b) has been increasing. This study was conducted to investigate the effect of esophagectomy (ES), endoscopic therapy (ET), and radiotherapy (RT) on long-term survival in elderly patients with cT1N0M0 esophageal cancer. METHODS:We searched t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13080

    authors: Qin J,Peng Y,Chen W,Ma H,Zheng Y,Li Y,Wang J

    更新日期:2019-07-01 00:00:00

  • Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study.

    abstract:BACKGROUND:  The optimal strategy was not established for patients who initially responded to gefitinib although re-administration of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been proven to be an option. Gefitinib and erlotinib were compared as salvage treatment after gefitinib fail...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/j.1759-7714.2012.00152.x

    authors: Yu S,Wang Y,Li J,Hao X,Wang B,Wang Z,Zhang X,Shi Y

    更新日期:2013-05-01 00:00:00

  • Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis.

    abstract:BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13235

    authors: Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

    更新日期:2020-02-01 00:00:00

  • Epidemiology of lung cancer in China.

    abstract:BACKGROUND:Lung cancer is the most common cancer and the leading cause of cancer death in China. Along with socioeconomic development, environmental problems have intensified and the burden of lung cancer continues to increase. METHODS:In this study, national cancer registry data was used for evaluating incidence, mor...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12169

    authors: Chen W,Zheng R,Zeng H,Zhang S

    更新日期:2015-03-01 00:00:00

  • Attempt of peripheral nerve reconstruction during lung cancer surgery.

    abstract:BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12619

    authors: Li H,Hu Y,Huang J,Yang Y,Xing K,Luo Q

    更新日期:2018-05-01 00:00:00

  • Chinese expert consensus on diagnosis and management of acquired respiratory-digestive tract fistulas.

    abstract::Acquired respiratory-digestive tract fistulas occur with abnormal communication between the airways and digestive tract, causing the interflow of gas and liquid. Despite advances in surgical methods and the development of multimodal therapy in recent years, patients with acquired respiratory-digestive tract fistulas c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12856

    authors: Wang H,Ke M,Li W,Wang Z,Li H,Cong M,Zeng Y,Chen L,Lai G,Xie B,Zhang N,Li W,Zhou H,Wang X,Lin D,Zhou Y,Zhang H,Li D,Song X,Wang J,Wu S,Tao M,Sha Z,Tan Q,Han X,Luo L,Ma H,Wang Z

    更新日期:2018-11-01 00:00:00

  • Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review.

    abstract::Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13600

    authors: Shan Q,Wang H,Han X,Guo J,Wang Z

    更新日期:2020-10-01 00:00:00

  • Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma.

    abstract:BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13008

    authors: Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

    更新日期:2019-04-01 00:00:00

  • Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.

    abstract:BACKGROUND:This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. METHODS:Data (N = 15) on patients' characteristics, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13241

    authors: Fujita K,Yamamoto Y,Kanai O,Okamura M,Hashimoto M,Nakatani K,Sawai S,Mio T

    更新日期:2020-01-01 00:00:00

  • RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules.

    abstract:BACKGROUND:To distinguish early-stage lung cancer from benign disease in pulmonary nodules, especially lesions with ground-glass opacity (GGO), we assessed gene mutations of ctDNA in peripheral blood using targeted next-generation sequencing (NGS). METHODS:Single pulmonary nodule patients without mediastinal lymph nod...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13741

    authors: Jiang N,Zhou J,Zhang W,Li P,Liu Y,Shi H,Zhang C,Wang Y,Zhou C,Peng C,Zhang W,Hao Y,Sun Q,Li Y,Zhao X

    更新日期:2020-11-16 00:00:00

  • Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways.

    abstract:BACKGROUND:Scutellarin (SCU), a flavonoid isolated from Erigeron breviscapus (Vant.) Hand.-Mazz., increases autophagy and apoptosis in the adenocarcinoma A549 cell line, which is resistant to cisplatin. However, whether SCU alone has antitumor activity against non-small cell lung cancer (NSCLC) is unknown. METHODS:Cel...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12962

    authors: Cao P,Liu B,Du F,Li D,Wang Y,Yan X,Li X,Li Y

    更新日期:2019-03-01 00:00:00

  • Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma.

    abstract:BACKGROUND:Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13260

    authors: Lo H,Abel S,Finley G,Weksler B,Colonias A,Wegner RE

    更新日期:2020-02-01 00:00:00

  • Micro ribonucleic acid-93 promotes proliferation and migration of esophageal squamous cell carcinoma by targeting disabled 2.

    abstract:BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12242

    authors: Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

    更新日期:2015-07-01 00:00:00

  • FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas.

    abstract:BACKGROUND:Although FGF19 gene aberrations are associated with carcinogenesis and progression in human cancers, the roles of FGF19 genetic amplification and expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 amplification as a potential therapeutic target for LSCC are not well understood....

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12504

    authors: Zhang X,Kong M,Zhang Z,Xu S,Yan F,Wei L,Zhou J

    更新日期:2017-11-01 00:00:00

  • Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.

    abstract:BACKGROUND:A single institution retrospective analysis of 124 non-small cell lung carcinoma (NSCLC) patients was performed to identify whether disease-free survival (DFS) achieves incremental values when radiomic and genomic data are combined with clinical information. METHODS:Using the least absolute shrinkage and se...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13568

    authors: Kim KH,Kim J,Park H,Kim H,Lee SH,Sohn I,Lee HY,Park WY

    更新日期:2020-09-01 00:00:00

  • Three-dimensional (3D)-printed titanium sternum replacement: A case report.

    abstract::After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three-dimensional (3D)-printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stabilit...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13655

    authors: Wang W,Liang Z,Yang S,Feng Q,Nie X,Su G,Yuan W,Han Y

    更新日期:2020-11-01 00:00:00

  • Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes.

    abstract:BACKGROUND:Both hypoxia and oncogenic mutations rewire tumor metabolism. In this study, glucose and glutamine metabolism-related markers were examined in stage I - resectable stage IIIA non-small cell lung cancer (NSCLC). Furthermore, expression of metabolism-related markers was correlated with mutational status to exa...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13226

    authors: Meijer TWH,Looijen-Salamon MG,Lok J,van den Heuvel M,Tops B,Kaanders JHAM,Span PN,Bussink J

    更新日期:2019-12-01 00:00:00

  • MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

    abstract:BACKGROUND:Our recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remai...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13326

    authors: Zuo J,Zhao M,Fan Z,Liu B,Wang Y,Li Y,Lv P,Xing L,Zhang X,Shen H

    更新日期:2020-03-01 00:00:00

  • Metastasis in the subcarinal lymph node with unknown primary tumor.

    abstract::A 59-year-old man with previous anaplastic large cell T-cell lymphoma stage 3A was admitted with an isolated positron emission tomography(PET)-positive spot in a subcarinal lymph node. Diagnosis was achieved with endobronchial ultrasound-guided fine-needle aspiration demonstrating a well-differentiated squamous cell c...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2010.00039.x

    authors: Eckardt J,Olsen KE,Petersen H

    更新日期:2011-05-01 00:00:00

  • Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: A case report and review of the literature.

    abstract::For refractory or resistant small cell lung cancer (SCLC), there is no standard treatment. We report a case of refractory SCLC achieving complete remission and then developing fatal interstitial pneumonitis after treatment with single-agent nab-paclitaxel. The relevant literature has also been reviewed. In terms of ef...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2011.00086.x

    authors: Wang B,Yang J,Luo D,Qiao H,Xie Z,Zhang X,Wu Y

    更新日期:2012-02-01 00:00:00

  • Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma.

    abstract:BACKGROUND:The five-year survival rate of lung adenocarcinoma patients (LUAD) is very low,and the methods of predicting survival are a great obstacle for LUAD therapies. Endothelin receptor type B (EDNRB) gene is associated with tumorigenesis. In this study, we aimed to evaluate the predictive value of EDNRB on LUAD. ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13474

    authors: Wei F,Ge Y,Li W,Wang X,Chen B

    更新日期:2020-07-01 00:00:00

  • Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer.

    abstract:BACKGROUND:This study investigated the correlations between CXCR4 and VEGF-C expression and lymph node metastasis in non-small cell lung cancer (NSCLC). METHODS:Tumor specimens, lymph nodes, and normal lung tissues were obtained from 110 NSCLC patients who underwent complete resection. Quantitative reverse transcripti...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12500

    authors: Bi MM,Shang B,Wang Z,Chen G

    更新日期:2017-11-01 00:00:00

  • Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.

    abstract::Programmed cell death-1 immune checkpoint inhibitor (ICI) antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1. However, there are currently no reports which evaluate drug efficacy by continuous bronchoscopic observation. A 75-year-ol...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13390

    authors: Morikawa K,Kida H,Handa H,Inoue T,Miyazawa T,Mineshita M

    更新日期:2020-05-01 00:00:00

  • Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.

    abstract::SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a new clinical entity characterized by SMARCA4 inactivation and has a dismal prognosis because of rapid growth. Effective treatments for SMARCA4-DTS have not yet been developed. Most recently, anti-programmed cell death 1 receptor (PD-1) blockade has been effective f...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13215

    authors: Takada K,Sugita S,Murase K,Kikuchi T,Oomori G,Ito R,Hayasaka N,Miyanishi K,Iyama S,Ikeda H,Kobune M,Emori M,Kato J,Hasegawa T

    更新日期:2019-12-01 00:00:00

  • Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β-catenin signaling pathway.

    abstract:BACKGROUND:Capn4 and ZEB1 play important roles in the metastasis of several types of cancer. However, the roles and relationship of Capn4 and ZEB1 in esophageal squamous cell carcinoma (ESCC) remain unclear. METHODS:ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 86 patient...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12893

    authors: Zhao YL,Li JB,Li YJ,Li SJ,Zhou SH,Xia H

    更新日期:2019-01-01 00:00:00

  • Flap endonuclease-1 rs174538 G>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.

    abstract:BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12422

    authors: Sang Y,Bo L,Gu H,Yang W,Chen Y

    更新日期:2017-05-01 00:00:00